Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium-glucose cotransporter 2 inhibitors: a retrospective study.
SGLT‐2 inhibitor
pancreatic fat
terms: type 2 diabetes
Journal
Obesity science & practice
ISSN: 2055-2238
Titre abrégé: Obes Sci Pract
Pays: United States
ID NLM: 101675151
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
03
10
2020
revised:
03
01
2021
accepted:
12
01
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
Prior reports have suggested that pancreatic fat is related to type 2 diabetes. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are expected to reduce ectopic fat accumulation. This study assessed the effect of SGLT-2 inhibitors on pancreatic and liver fat accumulations in patients with type 2 diabetes. Retrospective analyses of indices of pancreatic and liver fat accumulations were conducted in 22 type 2 diabetes outpatients who were receiving SGLT-2 inhibitors for more than 12 weeks. The differences between the pancreatic (P) or liver (L) and splenic (S) computed tomography values were evaluated. Fatty pancreas was defined as P-S < -8 Hounsfield Unit (HU), and the number of patients with fatty pancreas was 11 (50%). Fatty pancreas significantly improved after SGLT-2 inhibitor use (median, -20.8; IQR, -34.8 to -14.3 HU vs. median, -14.6; IQR, -29.5 to -7.8 HU; Pancreatic fat and liver fat accumulations might be reduced after treatment with SGLT-2 inhibitors in type 2 diabetes patients with intense cumulative fat depositions in these organs.
Sections du résumé
BACKGROUND
BACKGROUND
Prior reports have suggested that pancreatic fat is related to type 2 diabetes. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are expected to reduce ectopic fat accumulation.
AIM
OBJECTIVE
This study assessed the effect of SGLT-2 inhibitors on pancreatic and liver fat accumulations in patients with type 2 diabetes.
MATERIALS AND METHODS
METHODS
Retrospective analyses of indices of pancreatic and liver fat accumulations were conducted in 22 type 2 diabetes outpatients who were receiving SGLT-2 inhibitors for more than 12 weeks. The differences between the pancreatic (P) or liver (L) and splenic (S) computed tomography values were evaluated.
RESULTS
RESULTS
Fatty pancreas was defined as P-S < -8 Hounsfield Unit (HU), and the number of patients with fatty pancreas was 11 (50%). Fatty pancreas significantly improved after SGLT-2 inhibitor use (median, -20.8; IQR, -34.8 to -14.3 HU vs. median, -14.6; IQR, -29.5 to -7.8 HU;
CONCLUSION
CONCLUSIONS
Pancreatic fat and liver fat accumulations might be reduced after treatment with SGLT-2 inhibitors in type 2 diabetes patients with intense cumulative fat depositions in these organs.
Identifiants
pubmed: 34123402
doi: 10.1002/osp4.482
pii: OSP4482
pmc: PMC8170578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
346-352Informations de copyright
© 2021 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Junji Kozawa is a staff member of the endowed chair (Department of Diabetes Care Medicine) established by funds from Mitsubishi Tanabe Pharma Co.; AstraZeneca; Nippon Boehringer Ingelheim Co.; Taisho Pharmaceutical Co.; Ono Pharmaceutical Co.; MSD Co.; Keiseikai Hospital. Iichiro Shimomura has received lecture fees from Astellas Pharma, Inc.; MSD; Ono Pharmaceutical Co.; Kowa Pharmaceutical Co. Ltd.; Sanofi; Sanwa Kagaku Kenkyusho Co.; Takeda Pharmaceutical Co.; Mitsubishi Tanabe Pharma Co.; Eli Lilly Japan; Nippon Boehringer Ingelheim Co. and Novo Nordisk Pharma Ltd. and has received research funds from Astellas Pharma, Inc.; AstraZeneca; MSD; Ono Pharmaceutical Co.; Kyowa Kirin Co.; Kowa Company, Ltd.; Sanofi; Daiichi Sankyo Co.; Takeda Pharmaceutical Co.; Mitsubishi Tanabe Pharma Co.; Teijin Pharma Ltd.; Nippon Boehringer Ingelheim Co., Ltd; Novartis Pharmaceuticals Corp.; Novo Nordisk Pharma Ltd.; Taisho Pharmaceutical Co.; Sumitomo Dainippon Pharma Co.; Takeda Pharmaceutical Co.; Mitsubishi Tanabe Pharma Co.; Keiseikai Hospital; Gokeikai Osaka Kaisei Hospital; Midori Health Care Center; Suzuken Memorial Foundation; Japan Diabetes Foundation; Japan Foundation for Applied Enzymology; The Japan Diabetes Society and Terumo Co. Tomomi Horii, Shingo Fujita, Yoshiya Hosokawa, Takekazu Kimura, Yukari Fujita, Ayumi Tokunaga, and Kenji Fukui have nothing to declare.
Références
Hepatol Res. 2018 Feb;48(3):E42-E51
pubmed: 28628263
J Diabetes Investig. 2020 Jan;11(1):80-87
pubmed: 31240874
PLoS One. 2017 Jul 24;12(7):e0180911
pubmed: 28742102
Pancreas. 2018 Sep;47(8):e48-e50
pubmed: 29995705
Diabetes Care. 2018 Aug;41(8):1801-1808
pubmed: 29895557
Radiology. 2006 Apr;239(1):105-12
pubmed: 16484355
Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):577-87
pubmed: 16311218
Diabetes Obes Metab. 2019 Feb;21(2):285-292
pubmed: 30178600
Korean J Radiol. 2020 Apr;21(4):413-421
pubmed: 32193889
Lancet. 2013 Sep 14;382(9896):941-50
pubmed: 23850055
Invest Radiol. 2008 May;43(5):330-7
pubmed: 18424954
Endocr J. 2016 Jun 30;63(6):589-96
pubmed: 27052123
Gastroenterology Res. 2016 Dec;9(6):87-91
pubmed: 28058076
Int J Obes (Lond). 2015 Mar;39(3):480-7
pubmed: 25042860
Clin Anat. 2007 Nov;20(8):933-42
pubmed: 17879305
J Diabetes Investig. 2012 Aug 20;3(4):371-6
pubmed: 24843592
Clin Gastroenterol Hepatol. 2015 Mar;13(3):561-568.e1
pubmed: 25218667
J Clin Endocrinol Metab. 2015 May;100(5):2015-23
pubmed: 25734253
Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51
pubmed: 24622320
Diabetes. 2004 May;53(5):1311-7
pubmed: 15111501
BMJ Open Diabetes Res Care. 2020 Aug;8(1):
pubmed: 32784249
Radiology. 2014 Apr;271(1):104-12
pubmed: 24475851
Diabetes Metab Res Rev. 2010 Mar;26(3):200-5
pubmed: 20225188
Front Nutr. 2018 Sep 04;5:77
pubmed: 30234122
Endocr J. 2017 Mar 31;64(3):363-367
pubmed: 27980239